New IL12 treatment for those who fail Keytruda alone

› Forums › General Melanoma Community › New IL12 treatment for those who fail Keytruda alone

  • This topic is empty.
  • Post
    • November 9, 2017 at 8:32 pm
    Cooper
    Participant

      http://forum.melanomainternational.org/mif/il12-not-2-in-combination-with-pd1-encouraging-t36533.html

      More info on this trial: "The phase 2 results showed that the patients in the trial that took the combo therapy (ImmunoPulse IL-12 and Keytruda) achieved a 57% progression-free survival rate at 15 months. That is pretty impressive, especially when you consider the fact that these patients didn't respond at all with an anti-PD-1 alone. What's even better is the fact that 11 out of 11 or 100% of the patients had a duration of response. In addition, the median PFS has not yet been reached. If the long-term data continues to improve, then this biotech will continue to gain value. In addition, I can see Merck either partnering with OncoSec or outright acquiring it. As I note about the efficacy of the combination treatment, it is important to also state that it is very safe to take. The combination treatment not only works very well, but is highly tolerable for patients to take."

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.